methyl 6-(3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-5-((1-methyl-2-oxopyrrolidin-3-yl)oxy)benzamido)nicotinate | 1263402-57-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 6-(3-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-5-((1-methyl-2-oxopyrrolidin-3-yl)oxy)benzamido)nicotinate
• 英文别名: Methyl 6-[[3-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]-5-(1-methyl-2-oxopyrrolidin-3-yl)oxybenzoyl]amino]pyridine-3-carboxylate
• CAS: 1263402-57-8
• 化学式: C₂₈H₂₅N₅O₇
• 分子量: 543.536
• InChiKey: QZIXNDNQDZHQEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  146
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS
  申请人：Kharul Rajendra

  公开号：US20120184544A1

  公开（公告）日：2012-07-19

  The present invention relates to substituted benzamide derivatives of the general Formula I and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, prodrugs, metabolites, and polymorphs and can be useful for treating disease states mediated by glucokinase. Compounds disclosed herein can be used for reducing blood glucose levels and for increasing insulin secretion for treating type II diabetes. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds, and their use.

  本发明涉及一般式I的取代苯甲酰胺衍生物及其药用可接受的盐、药用可接受的溶剂化物、对映体、非对映体、前药、代谢物和多型体，可用于治疗由葡萄糖激酶介导的疾病状态。本文披露的化合物可用于降低血糖水平和增加胰岛素分泌，用于治疗2型糖尿病。本发明还涉及制备该化合物的方法、含有该化合物的药物组合物以及它们的用途。
• US8835469B2
  申请人：——

  公开号：US8835469B2

  公开（公告）日：2014-09-16
• [EN] SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS<br/>[FR] DÉRIVÉS DE BENZAMIDE SUBSTITUÉS UTILES COMME ACTIVATEURS DE LA GLUCOKINASE (GK)
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2011013141A2

  公开（公告）日：2011-02-03

  The present invention relates to substituted benzamide derivatives of the general Formula I and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, prodrugs, metabolites, and polymorphs and can be useful for treating disease states mediated by glucokinase. Compounds disclosed herein can be used for reducing blood glucose levels and for increasing insulin secretion for treating type II diabetes. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds, and their use.